Novel Therapeutic Anti-ADAM17 Antibody A9(B8) Enhances EGFR-TKI-Mediated Anticancer Activity in NSCLC

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) mutations are prevalent in non-small cell lung cancer (NSCLC), with EGFR tyrosine kinase inhibitors (EGFR-TKIs) showing initial efficacy.
• Acquired resistance to EGFR-TKIs, driven by specific EGFR mutations, limits long-term treatment success in NSCLC patients.
• Overexpression of a disintegrin and metalloprotease (ADAM) 17 is observed in NSCLC, suggesting its potential role in tumor progression and resistance.

Purpose of the Study:

• To investigate the combined anticancer effects of EGFR-TKI and a novel antibody A9(B8) targeting ADAM17 in NSCLC.
• To evaluate the efficacy of this combination therapy in overcoming EGFR mutation-associated drug resistance.
• To elucidate the molecular mechanisms underlying the enhanced anti-tumor activity of the combination treatment.

Main Methods:

• Utilized NSCLC cell lines with distinct EGFR mutations (e.g., L858R, T790M) to assess drug responses.
• Administered EGFR-TKI in combination with the A9(B8) antibody targeting ADAM17.
• Analyzed the phosphorylation status of extracellular signal-regulated kinases (ERK) to understand downstream signaling effects.

Main Results:

• The combination of EGFR-TKI and A9(B8) demonstrated synergistic anticancer effects in NCI-H1975 NSCLC cells harboring L858R and T790M mutations.
• This enhanced efficacy was associated with the simultaneous suppression of extracellular signal-regulated kinases (ERK) phosphorylation.
• The findings indicate that targeting ADAM17 can potentiate the anti-tumor activity of EGFR-TKIs.

Conclusions:

• Targeting ADAM17 alongside EGFR inhibition represents a promising strategy to enhance anti-NSCLC treatment efficacy.
• This combination approach holds potential for overcoming acquired resistance to EGFR-TKIs resulting from specific EGFR mutations.
• The study highlights the therapeutic value of dual targeting in managing complex oncogenic signaling pathways in NSCLC.